Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
8/21/25 | NicOx (COX) | NCX 470 for Glaucoma / Ocular Hypertension (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
8/19/25 | Viking Therapeutics (VKTX) | VK2735 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
8/18/25 | Reunion | RE104 for Postpartum Depression (PPD) | Subscribers Only | Subscribers Only | Subscribers Only |
8/18/25 | Aptose (APTO) | tuspetinib for Acute Myelogenous Leukemia (AML) | Subscribers Only | Subscribers Only | Subscribers Only |
8/15/25 | Pfizer (PFE) | Inclacumab for Sickle Cell Disease | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion (Emerging Markets) |
05/18/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
05/19/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |